{"id":19823,"date":"2022-05-31T09:57:17","date_gmt":"2022-05-31T13:57:17","guid":{"rendered":"https:\/\/medicarereport.org\/?p=19823"},"modified":"2022-05-31T09:57:19","modified_gmt":"2022-05-31T13:57:19","slug":"could-medicare-beneficiaries-see-a-decrease-in-medicare-premiums","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=19823","title":{"rendered":"Could Medicare beneficiaries see a decrease in Medicare premiums?"},"content":{"rendered":"\n<p>The Health and Human Services Secretary Xavier Becerra said: the overestimate in costs of covering an expensive and controversial new Alzheimer\u2019s drug will result in a Medicare premium adjustment. However, it will not happen this year or how much of an adjustment it will be. Since the drug manufacturer has cut the cost of the drug in half, and the limitations on coverage by Medicare, CMS could pass the savings on to Medicare beneficiaries. Read the article <a title=\"here\u2026\" href=\"https:\/\/apnews.com\/article\/health-xavier-becerra-medicare-government-and-politics-2ae8ccf461192e337d744bd5981fc192\">here\u2026<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"200\" height=\"135\" class=\"wp-image-8242\" style=\"width: 200px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/09\/HHS-seal.jpg\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/09\/HHS-seal.jpg 339w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/09\/HHS-seal-300x203.jpg 300w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:&nbsp;<\/strong>The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Health and Human Services Secretary Xavier Becerra said: the overestimate in costs of covering an expensive and controversial new<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[53,6,15],"tags":[],"class_list":["post-19823","post","type-post","status-publish","format-standard","hentry","category-hhs","category-medicare-general","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19823"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19823\/revisions"}],"predecessor-version":[{"id":19824,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/19823\/revisions\/19824"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}